New antibody drug takes on advanced tumors in first human trial
NCT ID NCT05143970
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tests an experimental drug called IPH5301, which targets a protein called CD73 on cancer cells. The study involves 27 people with advanced solid tumors, including breast, lung, and pancreatic cancers. In the first part, IPH5301 is given alone to find a safe dose. In the second part, it is combined with chemotherapy and trastuzumab for HER2-positive breast cancer patients. The goal is to check safety and find the right dose for future studies.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- IPH5301 (an experimental antibody targeting CD73), given alone or with chemotherapy (paclitaxel) and trastuzumab
- What this could lead to
- If successful, this could point toward a new treatment option for advanced cancers, especially HER2-expressing breast cancer, by helping the immune system fight tumors.
- What could go wrong
- This is a very early phase 1 trial with only 27 participants, so safety and dosing are still being figured out. The drug may not work or could cause serious side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Institut Paoli Calmettes
Marseille, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can your own immune cells beat advanced cancer?
- Can a new drug combo revive Immunotherapy's power against resistant tumors?
- What raises endometrial cancer risk in black women? a study digs in
- Tumor DNA mapping may unlock personalized cancer therapies
- Can a new drug combo shrink Hard-to-Treat tumors?
- Can a Two-Drug attack shrink Hard-to-Treat breast cancer?